BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10437915)

  • 1. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
    Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
    Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
    Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
    Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid.
    Zuco V; Zanchi C; Cassinelli G; Lanzi C; Supino R; Pisano C; Zanier R; Giordano V; Garattini E; Zunino F
    Cell Death Differ; 2004 Mar; 11(3):280-9. PubMed ID: 14657960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
    Chang FL; Ling YF; Lai MD
    Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
    Anthoney DA; McIlwrath AJ; Gallagher WM; Edlin AR; Brown R
    Cancer Res; 1996 Mar; 56(6):1374-81. PubMed ID: 8640828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line.
    Siddik ZH; Mims B; Lozano G; Thai G
    Cancer Res; 1998 Feb; 58(4):698-703. PubMed ID: 9485023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
    Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line.
    Asada N; Tsuchiya H; Tomita K
    Anticancer Res; 1999; 19(6B):5131-7. PubMed ID: 10697522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
    Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
    Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
    Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
    Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
    Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
    Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
    Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
    Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II).
    Husain A; Rosales N; Schwartz GK; Spriggs DR
    Gynecol Oncol; 1998 Jul; 70(1):17-22. PubMed ID: 9698467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis.
    Ganly I; Kim YT; Hann B; Balmain A; Brown R
    Gene Ther; 2001 Mar; 8(5):369-75. PubMed ID: 11313813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line.
    Fajac A; Da Silva J; Ahomadegbe JC; Rateau JG; Bernaudin JF; Riou G; Bénard J
    Int J Cancer; 1996 Sep; 68(1):67-74. PubMed ID: 8895543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.